IMMX stock news

IMMX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

15 wire items

2026-09-30 22:34:44 UTC#394979updateconfirmedpress release

Immix Biopharma (IMMX) closes $125 million underwritten common stock offering

reutersimportance 0.40trust 1.00Immix Biopharma, Inc. -0.30

2026-09-30 21:13:00 UTC#394591updateconfirmednews

Immix Biopharma prices $125M common stock offering at $11.00 per share

tradingviewimportance 0.50trust 0.90Immix Biopharma, Inc. -0.40JPMorgan Chase & Co. -0.10NXC-201 +0.10

2026-09-29 17:04:00 UTC#386114newconfirmednews

Needham maintains Buy rating on Immix Biopharma, raises price target to $30 from $21

dow_jonesimportance 0.40trust 0.70Immix Biopharma, Inc. +0.50Needham & Company, LLC +0.50

2026-09-29 13:56:57 UTC#384777updateconfirmednews

Immix Biopharma's NXC-201 shows 98% complete response rate in relapsed/refractory AL amyloidosis trial

quartrimportance 0.50trust 0.60Immix Biopharma, Inc. +0.70NXC-201 +0.70

2026-09-29 13:13:39 UTC#384408newconfirmednews

Immix Biopharma shares gain on positive mid-stage clinical trial data for AL amyloidosis therapy

seeking alphaimportance 0.50trust 0.60Immix Biopharma, Inc. +0.60

2026-09-29 11:33:56 UTC#383680newconfirmednews

Immix Biopharma prices $125M public stock offering

seeking alphaimportance 0.40trust 0.70Immix Biopharma, Inc. -0.30

2026-09-15 13:52:00 UTC#314326newconfirmednews

Mizuho maintains Outperform rating on Immix Biopharma (IMMX)

dow_jonesimportance 0.30trust 0.60Immix Biopharma, Inc. +0.10Mizuho Financial Group, Inc. +0.10

2026-09-14 23:01:06 UTC#310614duplicateconfirmednews

ImmunoGen's NXC-201 CAR T therapy shows efficacy in AL amyloidosis; pivotal data and BLA submission pending

quartrimportance 0.30trust 0.50ImmunoGen, Inc. +0.60NXC-201 +0.60

2026-09-14 22:07:25 UTC#310443newconfirmednews

ImmunoGen reports positive efficacy and safety for NXC-201 in AL amyloidosis, advancing toward approval

quartrimportance 0.40trust 0.50ImmunoGen, Inc. +0.60NXC-201 +0.60AL amyloidosis +0.50

2026-09-14 15:45:30 UTC#308540newconfirmednews

ImmunoGen files NDA for varegacestat in desmoid tumors, advances ROR1 ADC pipeline

quartrimportance 0.50trust 0.60ImmunoGen, Inc. +0.50varegacestat +0.60ROR1 +0.30

2026-08-11 16:06:00 UTC#159955newconfirmednews

Morgan Stanley cuts Immix Biopharma (IMMX) price target to $19 from $20, maintains Overweight rating

dow_jonesimportance 0.40trust 0.70Immix Biopharma, Inc. -0.30Morgan Stanley -0.10

2026-08-11 10:20:05 UTC#157823newconfirmednews

Immix Biopharma average analyst price target lowered to $20.44 from $20.56, maintains Buy rating

tradingviewimportance 0.30trust 0.70Immix Biopharma, Inc. +0.10

2026-08-10 12:19:00 UTC#152545newconfirmednews

Immix Biopharma (IMMX) price target raised to $25 from $20 at H.C. Wainwright & Co.

dow_jonesimportance 0.30trust 0.70Immix Biopharma, Inc. +0.50H.C. Wainwright & Co., LLC +0.50

2026-08-07 21:11:01 UTC#147631newconfirmeddata release

Immix Biopharma Q2 2026: $11.56M Net Loss, $(0.18) EPS; NEXICART-2 Enrollment Complete

tradingviewimportance 0.40trust 0.80Immix Biopharma, Inc. -0.30NEXICART-2 +0.40

2026-07-20 14:59:59 UTC#53072newconfirmednews

Immix Biopharma shares decline following termination of Chief Medical Officer

seeking alphaimportance 0.40trust 0.70Immix Biopharma, Inc. -0.50